Hongjoong holds a PhD from the Medical School, Newcastle University, U.K.Hongjoong is a senior drug development professional with more than 25 years’ experience in the life sciences industry. He has served in senior leadership positions in large international corporations and biotech companies prior to founding EnhancedBio.
“We have a mission to develop qualified drugs to treat patients suffering from their diseases. EnhancedBio is making a difference for the therapeutic benefit in favor of patients. I am very proud of our strong team for their contribution and commitment for our goal. I am confident that we will become a global leading biotechnology company.”
Dr. Hunsoon is an executive director and the CTO (Chief Technology Officer).
While being responsible for leading our R&D center, his primary focus is to develop pipelines & technologies and to advance them from fundamental research into clinical assets. His core strength includes but is not limited to the development of candidate product and process, supply chain, manufacturing, quality and CMC strategy, and non-clinical studies for IND. He has nearly 20 years of experience in the field of bioscience and pharmacology. During his doctoral studies at Seoul National University, Department of Pharmacy, he successfully established a drug discovery of siRNA therapeutics for cancer diseases. He has dedicated to advancing the innovative solution with one hope in his mind; patients being benefited from our drug development at the earliest opportunity.
“I am pleased to see consistent progress with our drug program. In aspect of the basic research and platform discovery, I believe that we are making a difference and this will be highly valued by cancer patients in the future. I hope that all our effort will help improve quality of life for everyone including patients and their loved ones. I am very enthusiastic to make this drive.”
Prior to joining EnhancedBio, Kyoungsun Ji worked for Doosan Corp - a major corporation in Korea with experience in excess of 20 years.
He has extensive experience and a strong skillset in general management, business management & strategy, and finance management
In EnhancedBio, Kyoungsun plays an essential role especially in division coordination & support, finance management, and IPO & holdings related matters.
“EnhancedBio is an extraordinary biotech company in Korea. We are composed of many outstanding talents here. This is certainly one team with a clear, distinct vision and great potential and foresight.
Without a doubt, what we have done and achieved are very valuable. EnhancedBio is committed to ambitiously make continued progress and see positive outcomes in the future.”
Bongsu Park is the director of regulatory affairs (RA) in EnhancedBio. He is primarily responsible for IND-enabling regulatory dossier as well as CTD-readiness package. From a regulatory angle, Bongsu provides oversight and leadership for non-clinical studies and manages all regulatory-related matters. With over 15 years of professional experience in toxicology and pharmacology, Bongsu acts as the bridge to close the gap between non-clinical to clinical stage.
“I sincerely feel proud of our progress and development that we are witnessing here in EnhancedBio. We do have the strength and capability to identify unmet needs of cancer patients and lead the way to successful launch of therapeutic agents. By succeeding in the development of world-class anti-cancer drugs, we will positively contribute to improve the quality of life for patients suffering from cancer-related diseases”